Sunshine Biopharma, Inc.
SBFM
$1.25
$0.032.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -72.66% | -83.85% | 45.21% | 24.59% | 94.68% |
| Total Depreciation and Amortization | 54.25% | 73.66% | 45.85% | 22.77% | 123.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -100.00% | 100.00% | -- | -- | -100.00% |
| Change in Net Operating Assets | 11.33% | -244.73% | -42.04% | -972.37% | -150.78% |
| Cash from Operations | -26.68% | -197.62% | -21.17% | -72.16% | -19.72% |
| Capital Expenditure | -126.83% | -5,285.42% | -114.18% | -- | 297.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 34.18% | -315.44% | 122.03% | -316.36% | -739.69% |
| Cash from Investing | -97.44% | -3,160.32% | -108.94% | -357.07% | 98.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 367.17% | -1.37% | 11.73% | 6.03% | -3.13% |
| Issuance of Common Stock | 70,256.52% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -519.51% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,834.43% | 3,033.96% | -100.70% | 1,102.81% | 98.55% |
| Foreign Exchange rate Adjustments | -245.84% | 302.49% | -287.54% | -16,196.00% | 87.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.32% | 179.11% | -1,461.47% | 145.10% | 86.36% |